HBM HOLDINGS-B (02142) surged more than 4%, reaching HK$13.49 by the time of writing, with a trading volume of HK$52.54 million. The company announced the launch of its Hu-mAtrIx™ AI-powered fully human HCAb (Heavy Chain Antibody) generation and screening model during its global R&D event in Shanghai on October 28.

This model, built on proprietary Harbour Mice® platform data, integrates a fine-tuned large language model (LLM) for sequence generation, enhanced by high-precision AI classification and druggability prediction. Unlike traditional screening methods, the platform establishes a closed-loop process combining AI design, intelligent screening, and wet-lab validation.

The AI HCAb model is expected to accelerate the application of fully human HCAb in next-generation therapies—including multispecific antibodies, XDC (Xenobiotic-Drug Conjugates), in vivo CAR-T, and inhaled/oral macromolecule drugs—potentially reshaping biologics R&D. Leveraging AI and HCAb technology, HBM HOLDINGS-B aims to fast-track innovative therapies and identify unmet clinical needs through data-driven predictive workflows.